biostudies-literatureUnknown14Lopes-Ribeiro A<h4>Introduction and methods</h4>In this present work, coronavirus subfamilies and SARS-CoV-2 Variants of Concern (VOCs) were investigated for the presence of MHC-I immunodominant viral peptides using in silico and <i>in vitro</i> tools.<h4>Results</h4>In our results, HLA-A*02 haplotype showed the highest number of immunodominant epitopes but with the lowest combined prediction score. Furthermore, a decrease in combined prediction score was observed for HLA-A*02-restricted epitopes when the original strain was compared to the VOCs, indicating that the mutations on the VOCs are promoting escape from HLA-A2-mediated antigen presentation, which characterizes a immune evasion process. Additionally, epitope signature analysis revealed major immunogenic peptide loss for structural (S) and non-stFrontiers in immunology1229712https://www.ebi.ac.uk/biostudies/studies/S-EPMC10656734biostudies-literatureSurveillance of SARS-CoV-2 immunogenicity: loss of immunodominant HLA-A*02-restricted epitopes that activate CD8⁺ T cells.PMC10656734Oliveira PMBarbosa-Stancioli EFda Fonseca FGLopes-Ribeiro ATsuji MCoelho-Dos-Reis JGARetes HMfalseSurveillance of SARS-CoV-2 immunogenicity: loss of immunodominant HLA-A*02-restricted epitopes that activate CD8⁺ T cells.<h4>Introduction and methods</h4>In this present work, coronavirus subfamilies and SARS-CoV-2 Variants of Concern (VOCs) were investigated for the presence of MHC-I immunodominant viral peptides using in silico and <i>in vitro</i> tools.<h4>Results</h4>In our results, HLA-A*02 haplotype showed the highest number of immunodominant epitopes but with the lowest combined prediction score. Furthermore, a decrease in combined prediction score was observed for HLA-A*02-restricted epitopes when the original strain was compared to the VOCs, indicating that the mutations on the VOCs are promoting escape from HLA-A2-mediated antigen presentation, which characterizes a immune evasion process. Additionally, epitope signature analysis revealed major immunogenic peptide loss for structural (S) and non-st2023-01-01T00:00:00Z20232026-04-27T03:17:30.269Z2025-04-05T19:22:55.442ZS-EPMC106567343802250610.3389/fimmu.2023.1229712